Skip to main content
. 2015 Mar 23;9(3):e0003610. doi: 10.1371/journal.pntd.0003610

Table 1. Characteristics of survey data, matched on location, from the ITI global prevalence database.

“Treatment” (with MDA) a (n = 170) “Background” (no MDA) a (n = 112)
No. % No. %
Countries represented
Burkina Faso 18 10.8 37 33.0
Ethiopia 25 15.0 10 8.8
Ghana 23 13.8 0 0.0
Mauritania 20 12.0 0 0.0
Nigeria 4 2.4 50 44.6
Vietnam 25 13.2 0 0.0
Burundi, Guinea, Guinea Bissau, Kenya, Malawi, Mali, Morocco, Mozambique, Nepal, Niger, Sudan, Tanzania, The Gambia 55 32.4 15 13.4
Baseline TF Prevalence
Category 0: <5% 14 8.2 14 12.5
Category 1: 5–9.9% 27 15.9 22 19.6
Category 2: 10–29.9% 96 56.5 48 42.9
Category 3: 30–49.9% 23 13.5 26 23.2
Category 4: >50% 10 5.9 2 1.8
Follow-up TF Prevalence
Category 0: <5% 89 52.4 46 41.1
Category 1: 5–9.9% 30 17.7 21 18.8
Category 2: 10–29.9% 37 21.8 36 32.1
Category 3: 30–49.9% 14 8.2 8 7.1
Category 4: >50% 1 0.9
Years Between Surveys
1–2 years 25 14.7 1 0.9
3–4 years 51 30.0 13 11.6
5–6 years 43 25.3 36 32.1
7–9 years 35 20.6 14 12.5
>10 years 16 9.4 48 42.9
Rounds Between Surveys
0 Rounds 112 100
1–3 Rounds 91 53.5
4–5 Rounds 36 21.2
>5 Rounds 18 10.6
 Missing b 25 14.7
Years Before Start of Treatment c
0 Years 56 32.9
1–2 Years 58 34.1
3–6 Years 26 15.3
7+ Years 5 2.9
 Missing b 25 14.7
Years Since Start of Treatment
1–3 Years 27 15.9
4–5 Years 80 47.1
6+ Years 38 22.4
 Missing b 25 14.7
Coverage Data
Any data, 2010–2012 52 28.4
 Missing 131 71.6

aPairs were sorted into the "treatment" dataset if any MDA had occurred in the interval between them.

b41 pairs in the treatment dataset were missing data on when treatment occurred.

cThese values represent the time interval between the baseline survey and the actual start of treatment.